SLIT2 and ZNF154 gene methylation detection primer probe set, kit and application in hepatocellular carcinoma detection
Through SLIT2 and ZNF154 gene methylation detection primer probe set and digital PCR technology, the accuracy and non-invasiveness in the diagnosis of hepatocellular carcinoma are solved, and the early detection of high sensitivity and specificity is achieved, reducing unnecessary surgery risk.
Patent Information
- Application Number
- CN202411244756.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-05
- Publication Date
- 2024-11-22
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing hepatocellular carcinoma diagnosis technology lacks high accuracy and non-invasiveness, resulting in some patients missing tests or performing unnecessary puncture surgery, insufficient sensitivity and specificity of imaging detection, and the accuracy of existing methylation detection methods also needs to be improve.
Develop primer probe sets and detection kits based on SLIT2 and ZNF154 gene methylation detection, combined with digital PCR technology, and methylation of cfDNA is achieved by designing 4-fold fluorescence detection for methylated and non-methylated probes. Absolute quantitative analysis, avoiding polyploid effect errors in internal reference gene method, is suitable for the diagnosis of early hepatocellular carcinoma.
Achieves high specificity and sensitivity detection of hepatocellular carcinoma, which can detect hepatocellular carcinoma early and distinguish benign space-occupying lesions, reduce unnecessary surgical risks, and have the lower limit of detection as low as single-digit copies. The results are more reliable and applicable on large-scale promotion.
Smart Images

Figure CN118995929A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene detection, and in particular to a primer probe set and a kit for detecting methylation of SLIT2 and ZNF154 genes, and their application in detecting hepatocellular carcinoma. Background Art
[0002] Liver cancer is one of the most common human tumors and can be divided into two major categories: primary and metastatic. Primary liver cancer mainly includes three different pathological types: hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (CCA) and mixed hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA). Hepatocellular carcinoma (HCC) accounts for about 75% of primary liver cancer.
[0003] Early diagnosis of HCC is crucial for early intervention and survival. Multiple studies have shown that early monitoring may improve overall survival, and international guidelines recommend that patients with cirrhosis should undergo HCC screening because the risk of HCC in patients with cirrhosis is between 2-4% per year. The American Association for Liver Diseases (AASLD) classifies the following patients as high-risk patients for developing HCC: patients with cirrhosis (Child Pugh stage A and B), patients with cirrhosis (Child Pugh stage C awaiting liver transplantation), and patients without cirrhosis but with HBV.
[0004] AASLD (American Association for the Study of Liver Diseases) currently recommends that high-risk patients undergo abdominal ultrasound surveillance every six months. However, less than one-fifth of high-risk patients undergo HCC screening. In addition, the sensitivity of abdominal ultrasound for detecting early HCC is only 45%. Additional screening using the AFP biomarker test may increase the detection rate of HCC, however, even with the combined approach, the sensitivity of detecting HCC is only 63%. The overall sensitivity of magnetic resonance imaging (MRI) and computed tomography (CT) for diagnosing HCC is 65% and 72%, respectively. However, for HCCs less than 2 cm, the sensitivities of CT and MRI are only 48% and 62%, respectively, and for HCCs less than 1 cm, the sensitivities of CT and MRI are even lower. Liver biopsy remains a reliable diagnostic tool for HCC, and percutaneous, ultrasound-guided liver biopsy is the most commonly used method. The main disadvantage of tissue biopsy is its invasiveness, and the most important risk is bleeding. Therefore, the clinical diagnostic needs of liver cancer are far from being met. Based on the concept of precision medicine, the development of new hematological diagnostics is a key strategy to improve the early diagnosis of HCC.
[0005] DNA methylation is a form of DNA chemical modification and plays an important role in gene expression regulation. It is a form of DNA chemical modification in which a methyl group is covalently bound to the 5th carbon position of cytosine in the CpG dinucleotide of the genome to form 5-methylcytosine (5mC) DNA, which can affect expression, gene-protein interaction, etc. without changing the DNA sequence. DNA methylation mainly occurs at CpG sites. Studies have shown that DNA methylation promotes the occurrence of cancer, and abnormal methylation of certain tumor-related genes can appear in the early stages of tumor development and can be used as a specific marker for diagnosis and monitoring.
[0006] Plasma free DNA (cfDNA) is released into the blood circulation due to cell apoptosis. In cancer patients, due to tumor cell necrosis or apoptosis, the tumor itself can also release a small amount of DNA into the blood circulation, called ctDNA. Analysis of this circulating tumor-derived DNA (ctDNA) can be used for early diagnosis of cancer. The emergence of new minimally invasive experimental methods, such as liquid biopsy, has provided a good environment for the development and application of methylation-based biomarkers, making cfDNA methylation an innovative biomarker for cancer.
[0007] Among the many methods for detecting methylation, real-time fluorescence quantitative PCR is one of the main methods, but it cannot absolutely quantify the methylation molecules, and the selection of reference targets is also affected by CNV variations, so the accuracy of detection needs to be improved.
[0008] Therefore, it is necessary to develop gene methylation detection primer probe sets and kits for hepatocellular carcinoma detection, so as to detect cfDNA methylation using digital PCR methods, which can be used as an effective supplement to imaging or tissue biopsy in the diagnosis of primary hepatocellular carcinoma. Summary of the invention
[0009] The main purpose of the present invention is to develop products based on gene methylation detection for auxiliary diagnosis of liver cancer, in view of the lack of high-accuracy non-invasive hepatocellular carcinoma auxiliary diagnosis technology in the current clinical frontline. Traditional imaging diagnosis, such as ultrasound, CT detection, etc., can make a diagnosis for most patients, but some patients cannot be diagnosed, resulting in missed detection of these patients, or unnecessary puncture surgery, which brings a large economic and physical burden to patients, and some non-invasive detection methods, such as AFP, are also less sensitive. The present invention provides SLIT2 and ZNF154 gene methylation detection primer probe groups, detection kits and related applications in the detection of hepatocellular carcinoma, so as to achieve specific, accurate, rapid and suitable for large-scale promotion of methylation gene detection, which can detect hepatocellular carcinoma at an early stage, and can also better distinguish benign space-occupying lesions from liver cancer, thereby reducing unnecessary surgery or puncture risks.
[0010] In view of this, the scheme of the present invention is:
[0011] In a first aspect of the present invention, a gene methylation detection primer probe set is provided, comprising a first probe primer set for detecting the SLIT2 gene and a second primer probe set for detecting the ZNF154 gene; the first primer probe set comprises a primer pair having a nucleotide sequence as shown in SEQ ID NO: 1-2, and a probe set having a nucleotide sequence as shown in SEQ ID NO: 3-4; the second primer set comprises a primer pair having a nucleotide sequence as shown in SEQ ID NO: 5-6, and a probe set having a nucleotide sequence as shown in SEQ ID NO: 7-8.
[0012] The second aspect of the present invention provides a SLIT2 and ZNF154 gene methylation detection kit, comprising the primer probe set described in the first aspect above.
[0013] Furthermore, each probe in the kit has a fluorescent group at the 5' end and a quenching group at the 3' end.
[0014] Furthermore, the kit also includes at least one of a PCR amplification system, a positive quality control product, a negative quality control product, a reference dye, and purified water.
[0015] Preferably, the PCR amplification system includes DNA polymerase, dNTP, Mg 2+ , PCR buffer system, PCR enhancer, PCR stabilizer, preferably Tris-KCl (10mM-500mM), (NH4)2SO4 (10mM-500mM), glycerol (1%-50%), BSA (0.001mg / mL-1mg / mL), betaine (0.1M-3M) and DMSO (0.1%-10%).
[0016] Furthermore, the final concentration of each primer pair is 0.2 μM, and the final concentration of each probe set is 0.1 μM.
[0017] The third aspect of the present invention provides the use of the kit described in the second aspect in the preparation of a hepatocellular carcinoma detection product.
[0018] A fourth aspect of the present invention provides a method for detecting SLIT2 and ZNF154 gene methylation for non-diagnostic purposes, comprising the following steps:
[0019] S1. Extract cfDNA from samples and perform sulfite conversion;
[0020] S2. Mixing the converted DNA, the primer probe set described in the first aspect and the qPCRProbe Master Mix to prepare a ddPCR mixture;
[0021] S3. placing the ddPCR mixture in a digital PCR instrument to perform a digital PCR amplification reaction;
[0022] S4. Collect multiple fluorescent signals from the products after PCR amplification reaction, and determine the methylation status of SLIT2 and ZNF154 genes according to the type of fluorescent signals.
[0023] In the above-mentioned detection methods, non-diagnostic detection includes detection of samples that cannot be traced back to humans, such as detection of gene methylation of a sample under laboratory conditions. The detection result only represents the result of the sample itself, that is, detecting the presence or absence of methylation of SLIT2 and ZNF154 genes.
[0024] Furthermore, in step S3, the ddPCR mixture is added into a digital PCR instrument, and the ddPCR mixture is made into 15,000-20,000 micro-reaction droplets.
[0025] Furthermore, in step S3, the PCR amplification reaction procedure is as follows: start heating the droplets at 60°C for 5 minutes, hot start at 95°C for 10 minutes; denaturation at 95°C for 20 seconds, annealing at 57°C for 40 seconds, for a total of 40 cycles.
[0026] Compared with the prior art, the beneficial effects of the present invention are:
[0027] The primer probe set for detecting SLIT2 and ZNF154 gene methylation of the present invention does not require additional internal reference genes, and detects methylated targets and non-methylated targets simultaneously, thereby avoiding the result error caused by the polyploidy effect commonly seen in cancer cells compared to the internal reference gene method; in addition, under the premise of ensuring system performance, the amplicon is designed to be as short as possible to adapt to the characteristics of short fragments of cfDNA. It has been verified that the use of the primer probe combination to detect SLIT2 and ZNF154 gene methylation has good specificity and high sensitivity; it can be used as an effective supplement to imaging or tissue biopsy in the diagnosis of primary hepatocellular carcinoma.
[0028] The detection kit of the present invention can realize 4-fold fluorescence detection in combination with the Sinafo digital PCR instrument. The primer probes are designed at the CpG sites near the target gene or the promoter of the target gene. For the CpG sites to be detected, probes for methylation and non-methylation are designed respectively, and different fluorescent markers are used to distinguish them. Digital PCR is used to absolutely quantify the number of methylated and non-methylated molecules, so as to accurately obtain the methylation ratio. Compared with the most common qPCR, this method has the following advantages:
[0029] a) High sensitivity, with a detection limit as low as single-digit copies, thus enabling the capture of low-level cancer signals;
[0030] b) High precision, able to distinguish small differences in methylation ratios between cancer and normal people, and the results are more reliable;
[0031] c) Eliminate interference from various PCR inhibitors and have wider applicability. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the drawings required for use in the embodiments are briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without creative work.
[0033] Figure 1 This is a design diagram of the primer probe for the SLIT2 gene methylation site of the present invention.
[0034] Figure 2 This is a design diagram of the primer probe for the ZNF154 gene methylation site described in the present invention.
[0035] Figure 3 This is an example diagram of a 50% methylated sample (FAM and VIC) in an embodiment of the present invention. DETAILED DESCRIPTION
[0036] In order to make the purpose, technical solution and beneficial technical effect of the present invention clearer, the present invention is further described in detail below in conjunction with the accompanying drawings and specific implementation methods. It should be understood that the specific implementation methods described in this specification are only for explaining the present invention, not for limiting the present invention.
[0037] In one embodiment, 30 methylation targets were selected from millions of methylation sites through RRBS detection of 500 clinical samples and public databases. However, due to the large number of sites, the system has poor cost and practicality. For this reason, we selected 12 targets from them, and finally screened out 2 targets through the detection of an additional 122 samples, and determined the appropriate threshold. Although the performance of this dual-target system is slightly worse than that of 30 targets, it is still much higher than traditional protein detection such as AFP. In addition, it can be combined with multiple digital PCR technology to achieve multiple fluorescence detection. In this embodiment, the genes targeted are SLIT2 and ZNF154 genes, and the primers and probes are designed as follows: Figure 1-2As shown, the red part is the target to be detected. The primer probe is designed at the CpG site near the target gene or the promoter of the target gene. The detection site is confirmed by the previous RRBS methylation detection on cancer patients and healthy population cohorts to screen out the optimal differential methylation regions (DMRs). For the CpG sites to be detected, probes for methylation and non-methylation are designed respectively, and different fluorescent markers are used to distinguish them. Digital PCR is used to absolutely quantify the number of methylated and non-methylated molecules, so as to accurately obtain the methylation ratio.
[0038] In the above embodiment, the primer-probe combination of SLIT2 and ZNF154 genes does not require additional internal reference genes, and simultaneously detects methylated targets and unmethylated targets, thereby avoiding the result errors caused by the polyploidy effect common in cancer cells compared to the internal reference gene method; in addition, under the premise of ensuring the performance of the system, the amplicon is designed to be as short as possible to adapt to the characteristics of short fragments of cfDNA. It has been verified that the use of the above primer-probe combination to detect methylation of SLIT2 and ZNF154 genes has good specificity and high sensitivity.
[0039] Specifically, in the above embodiment, the primer-probe combination of the SLIT2 and ZNF154 genes is as shown in Table 1, and the probes are modified with fluorescein.
[0040] Table 1: 8 PCR primers and fluorescein labeling characteristics of 2 loci
[0041]
[0042]
[0043] It should be pointed out that not every primer design can achieve high sensitivity and specificity detection. There are two reasons for this: first, the same gene may have hundreds of CpG sites, and the detection efficiency of different CpG sites is somewhat different; second, the detection efficiency of different genes is different. By increasing the number of detected genes, the sensitivity and specificity can be improved to a certain extent, but the increase in the number of genes will greatly reduce the practicality of the detection. This embodiment screens millions of methylation sites within the genome, selects the best CpG sites, and the best gene combination, to achieve higher sensitivity and specificity, meet clinical needs, and take into account good applicability.
[0044] In another embodiment, a method for rapid detection of liver cancer methylation genes SLIT2 and ZNF154 is provided, comprising:
[0045] 1. Extraction and conversion of plasma free DNA (cfDNA);
[0046] 2. Using the nucleic acid solution obtained in step 1 as a template, a probe primer set is used to establish a digital PCR system for specifically amplifying the target nucleic acid sequence, and amplifying the target genes SLIT2 and ZNF154;
[0047] 3. Collect multiple fluorescent signals from the products after PCR amplification reaction, and determine the methylation status of SLIT2 and ZNF154 genes based on the type of fluorescent signals.
[0048] In the above example, the SLIT2 gene target sequence before transformation (chr4:20255044-20255123 (hg19), SEQ ID NO: 9) is:
[0049] GCCCTCCCCACAACAACCGGCCCCTGCATCTTAGCAGCCGTTGGAAG CCCCAGCTCTTTTACCGCCAAGTTCATCCTTGG
[0050] The sequence of the SLIT2 target after conversion is (CpG methylation, the underlined part is the target to be detected, SEQ ID NO: 10):
[0051] GTTTTTTTATAATAATCGGTTTTTGTATTTTAGTAGT CG TTGGAAGTTTTAGTTTTTTTATCGTTAAGTTTATTTTTGG
[0052] The target sequence of the ZNF154 gene (chr19:58220790-58220856 (hg19), before transformation, hereinafter referred to as SEQ ID NO: 11) is:
[0053] TAATATGCTGTCTGATTACGACCCATTTAAGAAAGGGCGAAGTCCCT CCACTGCCCTAGGACTTGGA
[0054] The sequence of the ZNF154 target after transformation is referred to as SEQ ID NO: 12 (CpG methylation, the underlined part is the target to be detected):
[0055] TAATATGTTGTTTGATTACGATTTATTTAAGAAAGGG CG AAGTTTTTTTA TTGTTTTAGGATTTGGA
[0056] In the above embodiment, the detection kit for detecting SLIT2 and ZNF154 methylation specifically includes the components shown in Table 2. The methylation positive quality control product in the kit is the SLIT2 and ZNF154 methylation gene sequence plasmid, and the methylation negative quality control product is the normal human genome transformed DNA sequence plasmid.
[0057] Table 2:
[0058]
[0059] In one embodiment, free DNA is obtained from plasma and combined with digital PCR methylation detection. Plasma samples were obtained from patients with hepatocellular carcinoma and healthy people, totaling 122 cases. The collection of all human samples and clinical data complied with the principles of the Declaration of Helsinki, and all participants signed written informed consent for the use of their plasma samples. Blood samples were collected by venous blood sampling of 10 mL before all participants were enrolled.
[0060] The sample types and numbers are shown in Table 3.
[0061] Table 3:
[0062] Sample Type number Hepatocellular carcinoma 62 Benign liver lesions (including 20 cases of liver cirrhosis) 40 Healthy people 20
[0063] The sample information and test results are shown in Table 4.
[0064] Table 4:
[0065] Target combination Sensitivity Specificity SLIT2 83.33% 88.70% ZNF154 83.87% 90.00% SLIT2+ZNF154 88.70% 91.94%
[0066] It is not difficult to see from Table 4 that the combined sensitivity of the two genes reached 89%. In the presence of interfering samples, the specificity reached 92%. 16 out of 20 liver cirrhosis samples were judged as negative, which makes up for the shortcomings of existing detection methods, such as conventional ultrasound, which cannot distinguish between liver cancer and other space-occupying lesions. It is of great significance for the timely detection of early cancer lesions.
[0067] Example
[0068] 1. Sample Pretreatment
[0069] Before testing, sample DNA extraction and conversion are required, using a plasma DNA extraction and sulfite conversion kit, and the kit QIAamp Circulating Nucleic Acid Kit (Qiagen) and EZ DNA Methylation-Lightning Kit (ZYMO RESEARCH) for sample pretreatment.
[0070] The plasma sample volume required by this kit should be greater than 2 ml, and pre-processed according to the instructions of the plasma DNA extraction and sulfite conversion kit. The treated plasma DNA can be directly used for detection by this kit.
[0071] 2. Sample testing
[0072] 1) Take out the kit which has been stored at -15 to -25°C and protected from light, and equilibrate the kit components to room temperature;
[0073] 2) Take out the corresponding number of 96-well plates or PCR reaction tubes;
[0074] 3) Calculate and transfer the corresponding amount of reagents according to the number of reactions performed in the experiment. The number of reactions is the amount of the test plus one positive quality control and one negative quality control. The remaining reagents are stored at -15 to -25°C in the dark.
[0075] 4) Prepare the reaction system according to the following scheme
[0076] Primer mix 3.2μL CY5.5 reference dye 0.5μL AceQqPCRProbeMasterMix 11μL Purified water 3.8μL Template solution 3μL
[0077] 5) Template solution refers to the sample mixed solution after pretreatment in 1, methylation positive quality control product, methylation negative quality control product, and blank control product;
[0078] 6) Seal the 96-well plate or cover the PCR reaction tube, shake evenly, centrifuge at 2000 rpm for 10 seconds, tear off the cover and place it in the Sinafo DQ24 digital PCR instrument;
[0079] 7) Perform PCR amplification under the following conditions:
[0080]
[0081] Note: The exposure time settings are as follows:
[0082] Serial number Software Parameters Setting Value Corresponding fluorescence 1 ExpChannel0 1000 FAM 2 ExpChannel1 500 HEX / VIC 3 ExpChannel2 750 ROX 4 ExpChannel3 2000 CY5 5 ExpChannel4 4000 CY5.5
[0083] 3. Results Analysis
[0084] 1) Result quality control: The total number of droplets is above 18,000. The fluorescence channels corresponding to the target genes in the test results of this kit are shown in the following table:
[0085] Fluorescence channels Target genes FAM SLIT2-methylation VIC SLIT2-unmethylated ROX ZNF154-methylation CY5 ZNF154-unmethylated
[0086] 2) Determine the threshold: Analyze the 2D maps of the positive and negative controls. The 50% methylation 2D map is divided into four areas: top, bottom, left, and right. Move the threshold line so that the elliptical signal area where the positive and negative control signals overlap is completely in the lower left area. An example of a 50% methylation sample is as follows: Figure 3 As shown (FAM and VIC).
[0087] 3) Analyze other sample thresholds and the software automatically calculates the methylation ratio.
[0088] 4. Quality Control
[0089] The kit contains positive and negative controls. These controls should be added to each reaction to detect whether the reaction is successful and to ensure the effectiveness of the reaction. The methylation ratio of the positive and negative controls should be within the valid range, as shown in the table below. If the ratio is outside its valid range, the test result is invalid.
[0090] Comparison results SLIT2 methylation ratio ZNF154 methylation ratio Positive control is effective ≥25.0% ≥40.0% Negative control is effective <2% <3%
[0091] 5. Interpretation of results
[0092] The determination of PCR results is shown in the following table:
[0093] SLIT2 methylation ratio ZNF154 methylation ratio result ≥4% NA Positive NA ≥5% Positive <4% <5% Negative
[0094] The present invention is not limited to what is described in the specification and implementation modes, and therefore other schemes and modifications can be easily implemented by those familiar with the art. Therefore, without departing from the spirit and scope of the general concept defined by the claims and their equivalents, the present invention is not limited to the specific details, representative designs, and illustrative examples shown and described herein.
Claims
1. A gene methylation detection primer probe set, characterized in that: It comprises a first probe primer set for detecting the SLIT2 gene and a second primer probe set for detecting the ZNF154 gene; the first primer probe set comprises a primer pair having a nucleotide sequence as shown in SEQ ID NO: 1-2, and a probe set having a nucleotide sequence as shown in SEQ ID NO: 3-4; the second primer set comprises a primer pair having a nucleotide sequence as shown in SEQ ID NO: 5-6, and a probe set having a nucleotide sequence as shown in SEQ ID NO: 7-8.
2. SLIT2 and ZNF154 gene methylation detection kit, characterized in that, Comprising the primer probe set according to claim 1.
3. The kit according to claim 2, characterized in that In the primer probe set, each probe has a fluorescent group at its 5' end and a quenching group at its 3' end.
4. The kit according to claim 2, characterized in that The kit also includes at least one of a PCR amplification system, a positive quality control product, a negative quality control product, a reference dye, and purified water.
5. The kit according to claim 4, characterized in that The PCR amplification system includes DNA polymerase, dNTP, Mg 2+ , at least one of a PCR buffer system, a PCR enhancer, and a PCR stabilizer.
6. The kit according to claim 2, characterized in that The final concentration of each primer pair was 0.2 μM, and the final concentration of each probe set was 0.1 μM.
7. Use of the kit according to any one of claims 2 to 6 in preparing a product for detecting hepatocellular carcinoma.
8. A method for detecting SLIT2 and ZNF154 gene methylation for non-diagnostic purposes, characterized in that the steps include: S1. Extract cfDNA from samples and perform sulfite conversion; S2. Mixing the converted DNA, the primer probe set according to claim 1 and the qPCRProbe Master Mix to prepare a ddPCR mixture; S3. placing the ddPCR mixture in a digital PCR instrument to perform a digital PCR amplification reaction; S4. Collect multiple fluorescent signals from the products after PCR amplification reaction, and determine the methylation status of SLIT2 and ZNF154 genes according to the type of fluorescent signals.
9. The detection method according to claim 8, characterized in that: In step S3, the ddPCR mixture is added into a digital PCR instrument, and the ddPCR mixture is made into 15,000-20,000 micro-reaction droplets.
10. The detection method according to claim 8, characterized in that: In step S3, the PCR amplification reaction procedure is as follows: start heating the droplets at 60°C for 5 minutes, hot start at 95°C for 10 minutes; denaturation at 95°C for 20 seconds, annealing at 57°C for 40 seconds, for a total of 40 cycles.
Citation Information
Patent Citations
Kit for detecting DNA methylation state of peripheral blood cells for analyzing hepatocellular carcinoma
CN108660217A
Methods of amplifying DNA to maintain methylation status
CN110741092A
Cancer detection methods
US20180216195A1
Cited By
Primer-probe set and kit for detecting methylation of slit2 and ZNF154 genes, and use thereof in detection of hepatocellular carcinoma
WO2026051460A1
